Provided by Tiger Trade Technology Pte. Ltd.

Ocular Therapeutix

8.33
+0.23002.84%
Post-market: 8.390.0600+0.72%18:59 EDT
Volume:3.47M
Turnover:28.89M
Market Cap:1.81B
PE:-5.86
High:8.45
Open:8.23
Low:8.18
Close:8.10
52wk High:16.44
52wk Low:5.80
Shares:217.69M
Float Shares:191.00M
Volume Ratio:1.01
T/O Rate:1.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4203
EPS(LYR):-1.4203
ROE:-54.85%
ROA:-26.66%
PB:2.77
PE(LYR):-5.86

Loading ...

Ocular Therapeutix (OCUL) Is Down 10.9% After Pivoting AXPAXLI To Single-Trial NDA Pathway – Has The Bull Case Changed?

Simply Wall St.
·
Dec 19, 2025

RBC Capital Adjusts Ocular Therapeutix Price Target to $24 From $17, Maintains Outperform Rating

MT Newswires Live
·
Dec 16, 2025

Ocular Therapeutix Is Maintained at Buy by Chardan Capital

Dow Jones
·
Dec 09, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Five Below, Boeing, Instacart

Reuters
·
Dec 09, 2025

Ocular Therapeutix Stock Skyrockets On Faster FDA Path For Vision Drug

Benzinga_recent_news
·
Dec 09, 2025

Paramount Skydance, Wave Life Sciences, Ocular Therapeutix, Carvana And Other Big Stocks Moving Higher On Monday

Benzinga_recent_news
·
Dec 09, 2025

Ocular Therapeutix Up Over 27%, on Track for Highest Close Since May 2021 -- Data Talk

Dow Jones
·
Dec 09, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Micron, NextEra Energy, Ocular Therapeutix

Reuters
·
Dec 08, 2025

Ocular Therapeutix Shares Rise 25.1% on Plans to Fast-Track FDA Filing for Eye Disease Drug

THOMSON REUTERS
·
Dec 08, 2025

Ocular Therapeutix Inc : RBC Raises Target Price to $30 From $24

THOMSON REUTERS
·
Dec 08, 2025

Ocular Therapeutix Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Dec 08, 2025

BRIEF-Ocular Therapeutix Says SOL-1 Topline Data Expected In First Quarter 2026

Reuters
·
Dec 08, 2025

BUZZ-Ocular Therapeutix rises on plans to fast-track FDA filing for eye disease drug

Reuters
·
Dec 08, 2025

Ocular Therapeutix™ Announces Plans to Accelerate Nda Submission Timeline for Axpaxli™ in Wet Amd

THOMSON REUTERS
·
Dec 08, 2025

Ocular Therapeutix Inc - Sol-1 Topline Data Expected in First Quarter 2026

THOMSON REUTERS
·
Dec 08, 2025

AXPAXLI NDA Acceleration Might Change The Case For Investing In Ocular Therapeutix (OCUL)

Simply Wall St.
·
Dec 08, 2025

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Dec 05, 2025

Ocular Therapeutix Price Target Maintained With a $19.00/Share by HC Wainwright & Co.

Dow Jones
·
Nov 25, 2025

Analysts Are Bullish on Top Healthcare Stocks: Bioline RX Ltd Sponsored ADR (BLRX), Ocular Therapeutix (OCUL)

TIPRANKS
·
Nov 25, 2025

Ocular Therapeutix™ Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI™ in NPDR

GlobeNewswire
·
Nov 24, 2025